If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Director/PDMR Shareholding

10 Oct 2012 09:52

RNS Number : 3685O
Synectics PLC
10 October 2012
 



Synectics plc

(the "Company" or the "Group")

 

Award of Options under Revised Share Plan

Director PDMR shareholding

 

 

Synectics plc (AIM: SNX), a leader in the design, integration and control of advanced surveillance technology and networked security systems, announces that on 9 October 2012 it adopted a revised Executive Share Ownership Plan (the "Revised ExSOP") for Group executives, to replace its existing Executive Share Ownership Plan (the "existing ExSOP"), and made awards over 142,250 ordinary shares of 20p (the "Shares") to certain senior managers employed within the Group.

 

Under the Revised ExSOP, selected employees are entitled to exercise an option to receive a certain number of Synectics shares at any time after a 3 year vesting period, at no cost to themselves. The number of shares that are awarded at the end of the 3 year period is dependent on the achievement of certain performance criteria.

 

The performance criteria are identical to those that apply under the existing ExSOP. Provided that the total return on Synectics shares has out-performed the AIM All Share Total Return Index (the "Index") by 5% or more in the three years following the award, beneficiaries will be entitled to receive the full number of shares awarded. If Synectics' share performance matches the Index, then 25% of the awarded shares will vest and between these points vesting will be pro-rata. If the total return on Synectics shares underperforms the Index, then no entitlement will vest. The limit on the number of shares over which interests may be awarded also remains unchanged.

 

Any entitlement under the Revised ExSOP will lapse on cessation of employment prior to the end of the three year vesting period unless this is by reason of redundancy, ill health or death.

 

It is intended that if the performance criteria are met in full or part, the appropriate number of Shares will be transferred to the employees from unallocated Synectics shares already held within the employee benefit trust established for the existing ExSOP. 

 

Full details of the Revised ExSOP will be set out in the Company's Annual Report for the year ending 30 November 2012 which is expected to be issued in March 2013.

 

As a result of the award of options over the Shares referred to above, John Shepherd and Nigel Poultney, directors of the Company, have acquired an interest in 15,000 and 10,000 Synectics shares respectively.

 

In addition the Company has been notified that the Trustee of the Company's HMRC Approved Employee Share Acquisition Plan ("ESAP") has today purchased, in accordance with the ESAP's rules and on behalf of all ESAP participants, 6,547 ordinary shares of 20 pence each in the Company ("Ordinary Shares"), at a price of 272.5 pence each.

 

Under the terms of the ESAP, participating members, including employees and certain Directors of the Company, contribute a fixed amount to the Trustee on a monthly basis. The Trustee acquires a number of shares in the Company at the end of the contribution period (the "Period") (normally 6 months) based upon the contributions made in the preceding period and determined by the lowest share price at either the beginning of the Period or on the purchase day. In this instance the share price used for ESAP purposes was the price on the purchase day.

 

The Company was also notified that the above number of Ordinary Shares acquired by the Trustee included 189 Ordinary Shares, purchased as part of the reinvestment of the Company's interim dividend.  

 

As a result of these purchases, John Shepherd and Nigel Poultney, directors of the Company, have each acquired an interest in 289 Synectics shares.

 

 

 

Following the award of options over the Shares referred to above, and the share purchases in relation to the ESAP, the interests of John Shepherd and Nigel Poultney in Synectics shares are as follows:

 

Director

Position

B

Beneficial Interest

Interest in Share Schemes

ResultantTotalInterest

% ofIssuedShare Capital

John Shepherd

Chief Executive

58,972

402,202

461,174

2.62%

Nigel Poultney

Finance Director

13,000

221,864

234,864

1.34%

.

 

For further information, please contact:

Synectics plc

Tel: +44 (0) 1527 850080

Peter Rae, Senior Independent Director

www.synecticsplc.com

Westhouse Securities Limited

Tel: +44 (0) 207 601 6100

Tom Griffiths

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAPEEFSEAFEF
Date   Source Headline
27th Apr 202311:51 amRNSResult of AGM
27th Apr 20237:00 amRNSAGM Statement
13th Apr 20237:00 amRNSContract Award
4th Apr 20238:09 amRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSPosting of Accounts and Notice of AGM
14th Mar 20237:00 amRNSPDMRs' Interests in Shares
22nd Feb 20237:00 amRNSFinal Results
17th Feb 20237:00 amRNSDirectorate Change
13th Feb 20237:00 amRNSNotice of Results
13th Dec 20227:00 amRNSTrading Update
1st Dec 20227:00 amRNSCompletion of sale of non-core Business
11th Nov 20227:00 amRNSSale of non-core Business
7th Nov 20227:00 amRNSDirectorate Change
24th Oct 20227:00 amRNSBoard Change and Update on Chairman Recruitment
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSDirector’s and PDMRs' Interests in Share Schemes
12th Jul 20227:00 amRNSHalf-year Report
5th Jul 202212:00 pmRNSInvestor Presentation
5th Jul 20227:00 amRNSDirectorate Change
22nd Jun 20227:00 amRNSProposed Board Change
14th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSDirectorate Change
12th May 20228:12 amRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSAmendment to Performance Share Plan
10th May 20227:00 amRNSDirector/PDMR Shareholding
20th Apr 202212:05 pmRNSResult of AGM
20th Apr 20227:00 amRNSAGM Statement
4th Apr 202210:47 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSPosting of Accounts and Notice of AGM
8th Mar 20227:00 amRNSLong Term Infrastructure Contract
4th Mar 20227:00 amRNSAvailability of Annual Report and Accounts
22nd Feb 20227:00 amRNSFinal Results
16th Feb 20227:36 amRNSInvestor Presentation
2nd Feb 20227:00 amRNSNotification of Final Results
14th Dec 20217:00 amRNSContract for New Buses in Northern Ireland
8th Dec 20217:00 amRNSTrading Update
3rd Nov 20217:00 amRNSNew Casino Projects in North America
28th Oct 20217:00 amRNSMajor Project for West Midlands Police
1st Oct 20212:15 pmRNSDirector/PDMR Shareholding
23rd Aug 20217:00 amRNSContract Award for New Refinery Project
13th Jul 20217:00 amRNSHalf-year Report
14th Jun 20217:00 amRNSTrading Update
2nd Jun 20217:00 amRNSDirector/PDMR Shareholding
28th May 20217:00 amRNSDirector/PDMR Shareholding
11th May 20217:00 amRNSHolding(s) in Company
27th Apr 202111:22 amRNSResult of AGM
27th Apr 20217:00 amRNSBusiness Update
23rd Apr 20214:23 pmRNSHolding(s) in Company
7th Apr 20211:08 pmRNSDirector/PDMR Shareholding
7th Apr 20217:00 amRNSSynectics secures major City of London project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.